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Abstract: The standard regimen of second-line chemotherapy for patients with unresectable 
gastric cancer has not been established. However, weekly paclitaxel (wPTX) has become the 
preferable second-line chemotherapy in Japan. Histone deacetylase (HDAC) inhibitors have been 
shown to have antiproliferative activity through cell-cycle arrest, differentiation, and apoptosis 
in gastric cancer cells. One HDAC inhibitor, valproic acid (VPA), also inhibits tumor growth 
by inducing apoptosis, and enhances the efficacy of paclitaxel in a mouse xenograft model of 
gastric cancer. wPTX plus VPA as a second-line chemotherapy is expected to improve survival 
in gastric cancer patients. A multicenter randomized Phase II study was conducted to compare 
the effects of wPTX plus VPA and wPTX alone. A total of 66 patients participated in this 
study. The primary end point of the study was overall survival, and secondary end points were 
progression-free survival, response rate, and assessment of peripheral neuropathy.
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Introduction
Gastric cancer remains one of the leading causes of cancer death in the world. For 
patients with unresectable advanced or recurrent gastric cancer worldwide, the combi-
nation of fluoropyrimidine and platinum is standard first-line chemotherapy.1 Several 
randomized studies have revealed the survival benefit of second-line chemotherapy 
compared with best supportive care alone; however, median survival was less than 
6 months.2–4 Therefore, a more active regimen for second-line treatment is expected.
Although numerous clinical studies have considered the efficacy of molecularly 
targeted agents combined with conventional chemotherapy, efficacy in gastric cancer 
has been demonstrated only by trastuzumab as a first-line and ramucirumab as a second-
line treatment.5,6 Other candidates for molecularly targeted therapy are needed.
Histone deacetylase (HDAC) inhibitors have antiproliferative effects through 
cell-cycle arrest, differentiation, and apoptosis in various cancer cell types, including 
gastric cancer cells.7–9 Accordingly, the combination of an HDAC inhibitor with con-
ventional chemotherapy is expected to have a synergistic effect, because the mecha-
nism of action of the combination varies from those of conventional chemotherapeutic 
regimens. Valproic acid (VPA), which has long been used clinically for the treatment 
of epilepsy and bipolar disorder without significant toxic effects, is now also used to 
prevent migraines. VPA inhibits both class I and II HDACs,10 and affects tumor growth 
by inducing p21WAF1.11,12 However, some reports suggest that HDAC inhibitors also 
enhance the acetylation of nonhistone proteins in relation with apoptosis.13–15 Yagi 
et al reported that VPA induced dynamic modulation of histone H3 and α-tubulin 
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acetylation in relation with an anticancer effect and the 
enhancement of paclitaxel (PTX) in the gastric cancer cell 
line.16 The efficacy of VPA in human malignancy is unclear; 
however, combination therapy with radiotherapy revealed 
good prognosis in glioblastoma patients.17 Therefore, VPA in 
combination with PTX is expected to be a promising therapy 
for gastric cancer.
Weekly PTX (wPTX) administration of 80 mg/m2 is 
one treatment option for patients with gastric cancer in the 
second-line setting.18 A recent randomized Phase III trial 
comparing PTX and irinotecan as second-line chemotherapy 
for gastric cancer found no significant difference in overall 
survival (OS) between the two groups. Third-line che-
motherapy was administered to 89.8% of the participants 
in the PTX group and to 72.1% of those in the irinotecan 
group. Median OS was 9.5 months for PTX treatment and 
8.4 months for irinotecan treatment, respectively. However, 
wPTX was associated with a good toxicity profile compared 
with irinotecan.19
Therefore, we planned a multicenter randomized Phase II 
study to investigate additional benefits of VPA as a molecu-
larly targeting agent with wPTX in second-line or third-line 
chemotherapy.
Protocol design of the study
Purpose
The aim of this study was to compare the effects of wPTX 
alone and in combination with VPA (V-PTX) in patients with 
previously treated advanced gastric cancer.
End points
The primary end point was OS rate, defined as the time from 
randomization to death from any cause. Secondary end points 
were progression-free survival rate, defined as time from 
randomization to radiographic progression, and response rate 
and assessment of peripheral neuropathy in each therapeutic 
course. OS rate and progression-free survival rate were esti-
mated according to the Kaplan–Meier method. Response rate 
was evaluated every two courses during the study and classi-
fied based on Response Evaluation Criteria in Solid Tumors 
version 1.1. Toxicities including peripheral neuropathy were 
graded according to National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0.
Eligibility criteria
Patients over 20 years of age diagnosed with histologically 
confirmed metastatic or recurrent gastric carcinoma that was 
unresponsive to first-line or second-line therapy (progressive 
disease confirmed by imaging studies) were eligible to 
participate in the study. Other inclusion criteria were Eastern 
Cooperative Oncology Group performance status of 0–2, an 
interval of at least 4 weeks from the previous treatment, no 
prior chemotherapy with taxanes, adequate bone marrow, 
hepatic, and renal functions, and willingness to provide 
written informed consent.
Exclusion criteria were pregnancy, a history of allergy 
to Cremophor EL; intestinal pneumonia, lung fibrosis, and 
severe COPD; coexistence of another malignant neoplasm; 
psychological disease or brain metastasis; and other severe 
medical conditions.
Treatment methods
PTX (80 mg/m2) was administered intravenously on days 1, 8, 
and 15, every 4 weeks. Thirty minutes before PTX adminis-
tration, patients were premedicated with histamine receptor-1 
and -2 blockers and dexamethasone for prophylaxis of 
allergic reactions. VPA was administrated orally at a dose 
of 15 mg/kg/day divided into two daily doses. In this way, 
the serum value reached a concentration of 50–100 μg/mL, 
which is near the concentration required for VPA to act as an 
HDAC inhibitor (0.4–0.7 mM, 66.4–116.2 μg/mL).20
Study design
The study was a prospective, multicenter, randomized Phase II 
clinical trial. As of 2012, participating institutions included 
18 specialized centers. The protocol was approved by the 
independent ethics committee or institutional review board 
of each participating institution. This trial was conducted in 
accordance with the Declaration of Helsinki. All patients 
provided written informed consent before study entry.
After checking eligibility, patients were randomly 
assigned at a 1:1 ratio to receive VPA or not. Random assign-
ment was carried out at the data center using a minimiza-
tion method with the following adjustment factors: Eastern 
Cooperative Oncology Group performance status (0–1 vs 2), 
prior chemotherapy (first-line vs second-line), and measur-
able lesions (presence vs absence). Neither investigators nor 
patients were blinded to the allocated treatment.
Statistics
The reported median OS in advanced gastric cancer patients 
treated with wPTX as second-line chemotherapy was 5 and 
6.9 months, respectively.18,21 For an exploratory study, if the 
median OS times for V-PTX and PTX therapy were 5 and 
8 months, respectively, then 31 patients per treatment arm 
would be required to detect a difference with 80% power at 
a 5% significance level using a one-sided log-rank test of 
quality-of-survival curves. Assuming a dropout rate of 5%, 
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the number of patients per treatment group was set at 33, 
with a total sample size of at least 66 patients.
Protocol registration
The study protocol was registered with the UMIN (Univer-
sity hospital Medical Information Network) Clinical Trials 
Registry (UMIN000005887) on August 1, 2011.
Participating institutions
Departments of the following 18 centers in the Hokuriku 
region of Japan participated in the trial: Kanazawa University 
Hospital, Kurobe City Hospital, Toyama Rosai Hospital, 
Yatsuo General Hospital, Toyama Prefectural Central Hos-
pital, Toyama City Hospital, Takaoka City Hospital, Keiju 
General Hospital, Kanazawa Medical University Hospital, 
Ishikawa Prefectural Central Hospital, Asanogawa General 
Hospital, Keiju Kanazawa Hospital, JCHO Kanazawa Hos-
pital, Kanazawa Medical Center Hospital, Kanazawa Red 
Cross Hospital, Central Hospital of Matto Ishikawa, Houju 
Memorial Hospital, and Fukui University Hospital.
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The authors report no conflicts of interest in this work.
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